Is Veradermics, Incorporated (MANE) a Buy, Sell, or Hold?
NYSE : MANE
Veradermics, Incorporated
$105.83 USD
-$17.87 (-14.45%)
- Volume
- 1.31M
- Average Volume
- 671.96K
- Market Capitalization
- $4.42B
- P/E Ratio
- -67.84
- Dividend Yield
- 0.00%
- Price Target
- $170.00
- Year High
- $131.24
- Year Low
- $32.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $59.12
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Reid Waldman |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | MANE |
| CUSIP | 922967104 |
| CIK | 0001827635 |
| Web | https://www.veradermics.com |
| Phone | (228) 372-3376 |
| Currency | USD |
| Employees | 21 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 59.12 |
| Quick Ratio | 59.12 |
| Cash Ratio | 25.08 |
Sales & Book Value
| Annual Sales | -$ |
| Price / Sales | 0.00 |
| Cash Flow | -1.20 |
| Price / Cash Flow | -98.69 |
| Price / Book | 10.08 |
Price Target and Rating
| Average Stock Price Forecast | $170.00 |
| High Stock Price Forecast | $182.00 |
| Low Stock Price Forecast | $136.00 |
| Forecast Upside/Downside | -37.75% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 3 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$2.38 |
| Trailing P/E Ratio | -67.84 |
| PEG Ratio | -0.68 |
| P/E Growth | -0.68 |
| Net Income | -$70M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -84.21% |
| Return on Assets | -12.31% |
Financials Score
| AltmanZ Score | |
| Piotroski Score | |
| Working Capital | - |
| Total Assets | - |
| Ebit | - |
| Market Cap | - |
| Total Liabilities | - |
Poll Results
About Veradermics, Incorporated (NYSE:MANE) Stock
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as andro ... genetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months
2026-07-15 13:47:44
Veradermics Incorporated (NYSE:MANE) on Wednesday released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in women with mild-to-moderate pattern hair loss.
2026-07-15 13:07:57
Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 for Pattern Hair Loss Transcript
Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women
2026-07-15 10:05:21
Veradermics NYSE: MANE said results from the female arms of Study 207, a phase II open-label trial of VDPHL01 for mild to moderate pattern hair loss, showed what company executives described as a strong proof-of-concept signal for the oral treatment.
2026-07-15 07:00:00
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced positive topline results from its open-label Phase 2 clinical trial (Study ‘207') evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, in females with mild-to-moderate pattern hair loss. VDPHL01 has the potential to become the first FDA-approved oral.
2026-07-14 18:54:00
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Wednesday, July 15, 2026 at 8:00 am ET to review results from female treatment arms of the Phase 2 open-label Study ‘207' evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in males and females with mild-.
Biotech ETF Index Surges 10% After Rebalance
2026-06-25 11:31:47
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.
Can Veradermics (MANE) Climb 27.65% to Reach the Level Wall Street Analysts Expect?
2026-06-24 10:55:29
The mean of analysts' price targets for Veradermics (MANE) points to a 27.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2026-06-08 16:48:32
Veradermics, Incorporated (MANE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Frequently Asked Questions
-
What is the current Veradermics, Incorporated (MANE) stock price?
-
Veradermics, Incorporated(NYSE:MANE) stock price is $105.83 in the last trading session. During the trading session, MANE stock reached the peak price of $131.24 while $32 was the lowest point it dropped to. The percentage change in MANE stock occurred in the recent session was --14.45% while the dollar amount for the price change in MANE stock was -$17.87.
-
MANE's industry and sector of operation?
-
The NYSE listed MANE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MANE?
-
Mark Neumann | Chief Commercial and Strategy Officer
Michael V. Greco | General Counsel & Secretary
Michael Murphy | VP of Project & Program Management of Business Technology and Chief of Staff
Barbara Szymaszek | Director of Clinical Operations
Aron Shapiro | Vice President of Clinical Development & Regulatory Affairs -
How many employees does MANE have?
-
Number of MANE employees currently stands at 21. MANE operates from 470 James Street, New Haven, CT 06513, US.
-
Link for MANE official website?
-
Official Website of MANE is: https://www.veradermics.com
-
How do I contact MANE?
-
MANE could be contacted at phone #(228) 372-3376 and can also be accessed through its website. MANE operates from 470 James Street, New Haven, CT 06513, US.
-
How many shares of MANE are traded daily?
-
The average number of MANE shares traded daily for last 3 months was 671.96K.
-
What is the market cap of MANE currently?
-
The market value of MANE currently stands at $4.42B with its latest stock price at $105.83